S. Butt

What is meant by active disease in the NICE recommendation on use of combination therapy in early RA?

C. Deighton, R. Willott, K. Gadsby, 2012, Rheumatology.

Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.

R. Cooper, L. Kay, J. Ledingham, 2007, Rheumatology.

Neutropenia in patients receiving anti–tumor necrosis factor therapy

R. Moots, Weiya Zhang, C. Deighton, 2010, Arthritis care & research.

The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.

C. Deighton, N. Smith, K. Gadsby, 2007, Rheumatology.

Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis

G. Summers, D. Spina, S. Butt, 2012, Clinical Rheumatology.

The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice.

C. Deighton, N. Smith, T. Ding, 2008, Rheumatology.

Anti-TNF-&agr; Agents Are Less Effective for the Treatment of Rheumatoid Arthritis in Current Smokers

C. Deighton, A. Abhishek, K. Gadsby, 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern?

C. Deighton, K. Gadsby, S. Butt, 2007, Rheumatology.